BMO Capital analyst Gary Nachman maintained a Buy rating on 9 Meters Biopharma (NMTR – Research Report) today and set a price target of $5.00. The company's shares closed last Thursday at $0.83, close to its 52-week low of $0.82. According to TipRanks.com, Nachman is ranked 0 out of 5 stars with an average return of -5.6% and a 39.8% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Pacira Pharmaceuticals, and Ionis Pharmaceuticals. Currently, the analyst consensus on 9 Meters Biopharma is a Strong Buy with an average price target of $5.00.
https://www.tipranks.com/news/blurbs/bmo-capital-sticks-to-their-buy-rating-for-9-meters-biopharma-nmtr?utm_source=advfn.com&utm_medium=referral
9 Meters Biopharma (NASDAQ:NMTR)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more 9 Meters Biopharma Charts.
9 Meters Biopharma (NASDAQ:NMTR)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more 9 Meters Biopharma Charts.